H
Helmut R. Maecke
Researcher at University Hospital of Basel
Publications - 129
Citations - 9850
Helmut R. Maecke is an academic researcher from University Hospital of Basel. The author has contributed to research in topics: Somatostatin receptor & DOTA. The author has an hindex of 52, co-authored 127 publications receiving 9211 citations. Previous affiliations of Helmut R. Maecke include University of Basel & Instituto Superior Técnico.
Papers
More filters
Journal ArticleDOI
Biokinetics and imaging with the somatostatin receptor PET radioligand 68 Ga-DOTATOC: preliminary data
Michael Hofmann,Helmut R. Maecke,R Börner,E Weckesser,Patrick Schöffski,L Oei,J Schumacher,M Henze,A Heppeler,Joris Meyer,H Knapp +10 more
TL;DR: It is concluded that PET using 68Ga-DOTATOC results in high tumour to non-tumour contrast and low kidney accumulation and yields higher detection rates as compared with 111In-octreotide scintigraphy.
Journal Article
Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC.
Christian Waldherr,Miklos Pless,Helmut R. Maecke,Tilmann Schumacher,Armin Crazzolara,Egbert U. Nitzsche,Andreas R. Haldemann,Jan Mueller-Brand +7 more
TL;DR: High-dose targeted radiotherapy with 7.4 GBq/m(2) of the radiolabeled somatostatin analog (90)Y-DOTATOC is a well-tolerated treatment for neuroendocrine tumors, with remarkable clinical benefit and objective response.
Journal ArticleDOI
The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study.
TL;DR: Targeted radiotherapy with 90Y-DOTATOC is a novel, well-tolerated treatment for neuroendocrine tumours with a remarkable objective response rate, survival time, and symptomatic response.
Journal Article
Overview of Results of Peptide Receptor Radionuclide Therapy with 3 Radiolabeled Somatostatin Analogs
Dik J. Kwekkeboom,Jan Mueller-Brand,Giovanni Paganelli,Lowell Anthony,Stanislas Pauwels,Larry K. Kvols,Thomas M. O'Dorisio,Roelf Valkema,Lisa Bodei,Marco Chinol,Helmut R. Maecke,Eric P. Krenning +11 more
TL;DR: Treatment with radiolabeled somatostatin analogs is a promising new tool in the management of patients with inoperable or metastasized neuroendocrine tumors, and results obtained with [(90)Y-DOTA(0),Tyr(3)]octreotide and [(177)Lu-Dota(0,Tyr (3)] octreotate are very encouraging in terms of tumor regression.
Journal ArticleDOI
Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals?
Patricia Antunes,Mihaela Ginj,Hanwen Zhang,B. Waser,Richard P. Baum,Jean Claude Reubi,Helmut R. Maecke +6 more
TL;DR: This study demonstrates that 67/68Ga-DOTA-octapeptides show distinctly better preclinical, pharmacological performances than the 111In-labelled peptides, especially on sst2-expressing cells and the corresponding animal models, and may be excellent candidates for further development for clinical studies.